Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Basic guide to the mechanisms of antiestrogen action.
Forty years ago, Lerner and coworkers (1958) discovered the first nonsteroidal antiestrogen and Jensen (Jensen and Jacobson, 1960) identified a target for drug action, the ER. This knowledge opened… Expand
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
CONTEXT Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis. OBJECTIVE To… Expand
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
Raloxifene, a selective estrogen receptor modulator approved for the prevention and treatment of postmenopausal osteoporosis, has shown a significant reduction in breast cancer incidence after 3… Expand
Tamoxifen: a most unlikely pioneering medicine
- V. Jordan
- Nature Reviews Drug Discovery
- 1 March 2003
For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization lists tamoxifen… Expand
Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics.
- H. He, C. Meyer, M. Chen, V. Jordan, Myles Brown, X. S. Liu
- Biology, Medicine
- Genome research
- 1 June 2012
Transcription factor cistromes are highly cell-type specific. Chromatin accessibility, histone modifications, and nucleosome occupancy have all been found to play a role in defining these binding… Expand
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)–approved agent for reducing breast cancer risk but did not gain wide acceptance for… Expand
Most Plastic Products Release Estrogenic Chemicals: A Potential Health Problem That Can Be Solved
- C. Z. Yang, S. Yaniger, V. Jordan, D. Klein, G. Bittner
- Chemistry, Medicine
- Environmental health perspectives
- 2 March 2011
Background: Chemicals having estrogenic activity (EA) reportedly cause many adverse health effects, especially at low (picomolar to nanomolar) doses in fetal and juvenile mammals. Objectives: We… Expand
The biological role of estrogen receptors alpha and beta in cancer.
The temporal and tissue-specific actions of estrogen are mediated by estrogen receptors alpha and beta. The ERs are steroid hormone receptors that modulate the transcription of target genes when… Expand
International Union of Pharmacology. LXIV. Estrogen Receptors
- K. Dahlman-Wright, V. Cavaillès, +7 authors J. Gustafsson
- Biology, Medicine
- Pharmacological Reviews
- 1 December 2006
Estrogen receptors (ERs) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. In the late 1950s, the existence of a receptor molecule that could… Expand